Clinical trials: Epithelial Mesothelioma
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Malignant Pleural Mesothelioma
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.
- Trial name
- NCT03175172
- Testing
- CRS-207, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Aduro Biotech, Inc.
Malignant Pleural Mesothelioma
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into…
- Trial name
- Immuno-MESODEC (NCT05765084)
- Testing
- Dendritic cell vaccination, Atezolizumab, Platinum/pemetrexed based chemotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 15 people
- Sponsor
- University Hospital, Antwerp
Malignant Pleural Mesothelioma, Chemotherapy Effect
Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural lining with exceptionally poor survival. Median survival from diagnosis is less than 12 months (1).
- Trial name
- NCT05508555
- Testing
- hyperthermic intrathoracic chemotherapy
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Pleural Mesothelioma, Malignant Pleural Mesothelioma
Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma
The purpose of this study it to determine the safety and maximally tolerated dose (MTD) of cisplatin administered in the operating room and put into the chest and abdomen for one hour.
- Trial name
- NCT00165555
- Testing
- Cisplatin, Sodium Thiosulfate
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Mesothelioma
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have…
- Trial name
- NCT00027508
- Testing
- trabectedin
- Where
- 4 sites in United States
- Sponsor
- PharmaMar
Malignant Pleural Mesothelioma (MPM)
Multidimensional Omics Analysis in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited.
- Trial name
- OMIM (NCT07561190)
- Where
- 4 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Background: A germline mutation is a change to a person s genes that is carried through their DNA. These mutations can be passed on from parents to their offspring.
- Conditions
- Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS), Mesothelioma
- Trial name
- NCT04431024
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Meso-Immune is a retrospective study to assess the efficacy and safety of the combination of Nivolumab and Ipilimumab used in first-line treatment of adult patients with unresectable Malignant Pleural Mesothelioma (MPM).
- Trial name
- MESO-IMMUNE (NCT05308966)
- Testing
- Data collection
- Where
- 63 sites in France
- Volunteers
- 204 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases.
- Conditions
- Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- IMMUNORARE5 (NCT06790706)
- Testing
- DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
- Where
- 15 sites in France
- Volunteers
- 27 people
- Sponsor
- Hospices Civils de Lyon
Mesothelioma
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
Background: Standard therapy for mesothelioma is a combination of the drugs pemetrexed and cisplatin. However, the benefits of this treatment are limited, and in most treated patients the disease continues to worsen.
- Trial name
- NCT01445392
- Testing
- Multicycle SS1P, Pemetrexed, Cisplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
The purpose of this study is to evaluate, in patients with tumors known to express the protein mesothelin, the following properties of BAY2287411 injection: safety (to identify, assess, minimize, and appropriately manage the…
- Conditions
- Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, Advanced Recurrent Serous Ovarian Cancer, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
- Trial name
- NCT03507452
- Testing
- BAY2287411
- Where
- 7 sites in United States, Finland and 3 more
- Volunteers
- 36 people
- Sponsor
- Bayer
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural…
- Trial name
- NCT00535951
- Testing
- LBH589
- Where
- 5 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00066651
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Malignant Mesothelioma
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Trial name
- NCT00020124
- Testing
- doxorubicin hydrochloride
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Mesothelioma
Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients
Malignant mesothelioma is an aggressive pleural disease, related to asbestos exposure. At present, cytotoxic chemotherapy is the only evidence based treatment for the disease, but efficacy is limited.
- Trial name
- MesoCancerVa (NCT02395679)
- Testing
- MesoCancerVac
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- Erasmus Medical Center
Mesothelioma
Sorafenib in Previously Treated Malignant Mesothelioma
The principal objective of the study is to investigate the effect of sorafenib on progression free survival (time until the cancer begins to grow again,) in patients with malignant mesothelioma who have had prior treatment with…
- Trial name
- SMS (NCT00794859)
- Testing
- Sorafenib
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- King's College London
Lung Diseases, Mesothelioma
Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication
The goal of this clinical research study is to compare Progel® (a type of surgical sealant that is made from human blood products) to the standard of care (talcum powder) to learn if one method is better than the other for…
- Trial name
- NCT02511600
- Testing
- Progel Sealant, Talcum Powder, Pain Questionnaire
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-small-cell Lung, Mesothelioma
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
This study will explore whether defactinib (a FAK inhibitor) can be safely and tolerably combined with pembrolizumab (a PD-1 inhibitor) and will look for early indications of improved anticancer immunotherapy.
- Conditions
- Carcinoma, Non-small-cell Lung, Mesothelioma, Pancreatic Neoplasms
- Trial name
- NCT02758587
- Testing
- Defactinib, Pembrolizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 59 people
- Sponsor
- NHS Greater Glasgow and Clyde